Key Drivers
- Persistent losses
- Strong liquidity
- No debt
AIAI Summary
ANGO is evolving into a higher-growth Med Tech commercialization story, but after its rally investors should require proof that Auryon, NanoKnife, and AlphaVac growth converts into sustained EBITDA and free-cash-flow improvement; hold/watch for margin stabilization and operating leverage before chasing upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Persistent losses
- •Strong liquidity
- •No debt
ANGO has strong margins and liquidity with no debt, but persistent losses, high operating expenses, and a large retained deficit make profitability and investment appeal weak.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Below Average
- •Resistance Overhead
ANGO is slightly bearish over the last month, holding $15.20–$15.24 support but needing to reclaim $15.62–$15.68 resistance to improve momentum.
Rebounded from near $15.20 support to $15.68 in mid-September
Sentiment & News
Key News Insights:
- •BofA stake surge
- •CPP new position
- •No operational updates
Institutional investors significantly increased AngioDynamics exposure, signaling positive ownership momentum without new operational catalysts.
The purchases may support investor sentiment toward AngioDynamics, though they do not change its underlying business outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings